PPMO-based exon skipping therapy improves respiratory function in the <i>mdx</i> mouse model of Duchenne muscular dystrophy.

100 mg/kg PPMO-treated mice), while lower (30 mg/kg) and intermittent doses (50 mg/kg) showed a trend toward improved strength ( p < 0.05, WT and untreated mdx vs. lower and intermittent dose PPMO-treated mdx mice) ( Figure 6 A).

also in 33,237 other papers